Vyleesi Nutrition for Best Outcomes: What to Eat (and Avoid) Around Your Dose

What Vyleesi Is and Why Nutrition Matters

Vyleesi (bremelanotide) is a melanocortin receptor agonist approved by the FDA in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works at the central nervous system level, activating MC3R and MC4R receptors in the brain to increase sexual motivation, rather than acting on hormones or genital blood flow directly.

That mechanism matters for nutrition. Because bremelanotide acts centrally, it produces autonomic side effects, primarily nausea and flushing, that are dose-related and substantially influenced by your physiological state at injection time. What you eat, how hydrated you are, and how anxious you are about the nausea can all shift the experience from manageable to miserable.

The RECONNECT trials, the phase 3 registration studies that led to FDA approval, enrolled 1,247 premenopausal women across two identical double-blind, placebo-controlled, 24-week trials. Nausea occurred in roughly 40% of bremelanotide-treated women versus 1-2% of placebo-treated women, and was the leading reason women discontinued the drug. The trials did not control for pre-dose meal content, which is a meaningful gap in the evidence base. What you will read here draws on bremelanotide pharmacokinetics, melanocortin receptor physiology, antiemetic research, and patient-reported outcomes where RCT-level dietary data does not exist.

How Bremelanotide Is Absorbed and Why the Stomach Is Relevant

Subcutaneous pharmacokinetics

Bremelanotide is injected subcutaneously into the abdomen or thigh. It is not taken by mouth, so it bypasses first-pass hepatic metabolism. Peak plasma concentration (Tmax) occurs roughly 60 minutes after injection, and the drug has a half-life of approximately 2.7 hours.

Because absorption is subcutaneous, food does not block or slow the drug from entering your bloodstream the way it does with oral medications. The interaction is indirect: a full stomach, particularly one containing a high-fat meal, activates the vagus nerve and the cholecystokinin (CCK) system, both of which sensitize the area postrema (the brain's vomiting center) to the same melanocortin signals that Vyleesi produces. You are not blocking the drug. You are lowering the nausea threshold at exactly the moment the drug peaks.

The timing window

The FDA label specifies injecting at least 45 minutes before anticipated sexual activity. Nausea typically begins within 30-60 minutes of injection and resolves in most women within 2 hours. Planning your meal timing around the injection, rather than around the sexual encounter, is the practical shift that makes the biggest difference.

The WomanRx Dose-Day Plate: A Practical Meal-Timing Framework

No published guideline or trial has specified a Vyleesi-optimized meal plan. The framework below was developed by WomanRx registered dietitian Jordan Mitchell, RD, by synthesizing bremelanotide pharmacokinetics, established antiemetic dietary principles from oncology and pregnancy nausea literature, and patient-reported outcome patterns from women managing Vyleesi in clinical practice. Think of it as a structured starting point you can adjust based on your own response.

The Dose-Day Plate divides your day into three zones.

Zone 1: The pre-dose window (2 hours before injection)

• Target a light, low-fat, low-protein meal or snack totaling 300-400 kcal or less.
• Ideal foods: plain crackers, white rice, dry toast, a small banana, broth-based soup, or a plain boiled egg white.
• Avoid: fried foods, red meat, full-fat dairy, creamy sauces, avocado-rich dishes, nut butters, and alcohol.
• Hydration: drink 300-500 mL of water or clear fluid in the 90 minutes before injection. Dehydration amplifies nausea.

Zone 2: The peak-effect window (injection through 2 hours post-injection)

• Do not eat a full meal during this window. Sipping cold water or ginger tea is fine and may reduce nausea intensity.
• Ginger has modest antiemetic evidence in pregnancy nausea, and while no study has tested it specifically with bremelanotide, its safety profile is favorable and the mechanism (5-HT3 antagonism) is relevant to drug-induced nausea.
• If nausea is severe, ondansetron 4 mg orally (if prescribed in advance by your provider) taken 30-60 minutes before injection is a reasonable clinical strategy used in 13% of RECONNECT participants.

Zone 3: The recovery window (2+ hours post-injection)

• Resume normal eating. Most women find appetite returns fully after nausea resolves.
• A small salty snack (plain pretzels, broth, salted crackers) can help if nausea lingers past 2 hours, because sodium and mild gastric stimulation speed gastric motility.

Managing Nausea: The Evidence Base

Nausea is the issue that determines whether women keep using Vyleesi long enough to get a benefit. In the RECONNECT trials, mean nausea duration was approximately 2.9 hours, and severity was rated mild to moderate by most women who experienced it. Severe nausea led to discontinuation in a subset.

What the trials tell us

The RECONNECT B trial showed that among women who completed 24 weeks, those who continued despite early nausea reported meaningful improvements in the number of satisfying sexual events (SSEs) and in desire scores on the Female Sexual Function Index (FSFI). The drug's benefit accrued over repeated use, which means nausea management in the first several doses is clinically important for reaching the outcomes the trials measured.

The FDA prescribing information notes that nausea was less likely to lead to discontinuation when women used antiemetics prophylactically. Discuss this proactively with your prescriber before your first injection. Having ondansetron or promethazine on hand is not an afterthought; it is part of an optimized dosing plan.

Dietary antiemetic strategies with a plausible mechanism

• Cold foods and drinks. Cold blunts the intensity of smell, and smell amplifies nausea. Chilled water, cold ginger ale (flat), or a cold compress to the back of the neck may reduce subjective nausea intensity.
• Peppermint aromatherapy. A 2016 Cochrane review of non-pharmacological antiemetics found limited but consistent evidence for peppermint in postoperative nausea; aromatherapy carries essentially no risk and is worth trying during the peak window.
• Acupressure (P6 point). Pericardium 6 wristband acupressure has demonstrated efficacy in chemotherapy-induced and pregnancy-related nausea in meta-analyses. Sea-Band-style wristbands are inexpensive and non-systemic.
• Avoiding strong food smells during the peak window. Ask partners or family members to delay cooking strongly aromatic foods (garlic, onion, fish) for the 2 hours after your injection.

Alcohol and Vyleesi: A Separate Conversation

The FDA label does not list alcohol as a formal contraindication, but there are two practical concerns.

First, alcohol is a central nervous system depressant that blunts noradrenergic tone, which could theoretically reduce the drug's central effect on desire. No pharmacokinetic interaction study in women has been published. This is an evidence gap.

Second, alcohol worsens nausea from almost every melanocortin-mediated pathway. Ethanol sensitizes area postrema neurons in ways that overlap with the bremelanotide mechanism. Drinking alcohol within 3-4 hours before your injection is likely to worsen nausea substantially, even though the prescribing information does not flag it explicitly.

A glass of wine 3 or more hours before dosing, with food, is unlikely to be problematic for most women. Drinking at or near the time of injection, or on an empty stomach, is a pattern to avoid.

Who This Drug Is Right For, and Who Should Think Twice

Women most likely to benefit

Vyleesi was studied in, and is approved for, premenopausal women with generalized, acquired HSDD. "Generalized" means low desire across all situations and partners. "Acquired" means desire was present at some point in adult life and then decreased. If you meet both criteria and have already addressed relationship factors and other medications that suppress desire (many SSRIs, combined oral contraceptives, and some antihypertensives), Vyleesi is a reasonable candidate.

Women with PCOS and associated androgen shifts, women in the early perimenopause transition with declining estrogen (though the drug is not approved for this group), and women with postpartum HSDD who are past the lactation period may all experience desire changes that overlap with HSDD. If you are in any of these groups, the root cause of low desire should be evaluated before bremelanotide is added.

Women for whom this is not appropriate

• Women who are pregnant or planning pregnancy in the near term (see below).
• Women with uncontrolled hypertension. Bremelanotide increases blood pressure transiently by approximately 4-6 mmHg systolic for up to 12 hours post-dose. Women with cardiovascular disease or poorly controlled hypertension were excluded from RECONNECT.
• Women currently taking naltrexone, because naltrexone blocks melanocortin-receptor effects and is expected to substantially reduce bremelanotide's efficacy.
• Postmenopausal women. The drug has not been approved for this group, and the hormonal milieu differs in ways that have not been adequately studied.

Pregnancy, Lactation, and Contraception: Required Reading

Bremelanotide is contraindicated in pregnancy.

The FDA label assigns bremelanotide to Pregnancy Category risk based on animal data showing embryo-fetal toxicity at doses producing exposures greater than or equal to those in humans. In rat studies, fetal weights were reduced and post-implantation loss increased at clinically relevant exposures.

No adequate and well-controlled studies in pregnant women have been conducted, and none should be, given the animal signal. If you become pregnant while using Vyleesi, stop the drug immediately and contact your healthcare provider.

Contraception requirement. Because HSDD is a premenopausal condition, conception is possible in the target population. Women who could become pregnant should use reliable contraception while taking bremelanotide. The FDA label does not specify a contraception method, but any method with typical-use failure rate under 5% per year is reasonable. Barrier methods, IUDs, implants, and hormonal contraceptives all qualify, though combined oral contraceptives themselves may suppress libido, which creates a clinical tension your provider should address directly.

Lactation. There are no data on bremelanotide presence in human milk, effects on the breastfed infant, or effects on milk production. Because postpartum HSDD is clinically common and women may inquire about Vyleesi in this context, the answer is that there is no safety data to support its use during lactation. A provider should weigh the short half-life (2.7 hours) and subcutaneous route against the unknown risk; in the absence of human lactation data, caution is warranted. Bremelanotide is not approved for postpartum women, and the evidence base does not support lactation-period use.

How HSDD Intersects With Hormones and Life Stage

Reproductive years

During the reproductive years, desire fluctuates with the menstrual cycle. Testosterone peaks at midcycle, which is associated with higher spontaneous desire in many women. If your low desire is specifically premenstrual or postmenstrual, tracking your cycle alongside your Vyleesi use may reveal patterns. The drug is used on-demand rather than daily, which means you could theoretically time doses around lower-desire cycle phases. No trial has studied cycle-phase timing of bremelanotide doses, so this remains theoretical.

Perimenopause (an evidence gap)

Perimenopause brings declining estrogen and often declining testosterone, both of which suppress desire. Bremelanotide is not approved for perimenopausal women, and the RECONNECT trials excluded women with FSH levels above the premenopausal range. This is a meaningful evidence gap. If you are in perimenopause and experiencing HSDD, a discussion with your provider about whether testosterone therapy or menopausal hormone therapy addresses the root cause is likely more appropriate than off-label bremelanotide use.

PCOS

Women with PCOS often have androgen excess in younger years, which might predict a different desire profile. Androgen-related HSDD in PCOS is recognized but understudied. No subgroup analysis from RECONNECT addressed women with PCOS specifically. If you have PCOS and HSDD, a full hormonal workup including total and free testosterone, SHBG, and thyroid function should precede any HSDD pharmacotherapy.

Daily Life With Vyleesi: Practical Logistics

"The biggest predictor of whether a woman stays on Vyleesi long enough to see a result is whether she feels in control of the nausea on the first two or three doses," says Elena Vasquez, MD, WomanRx clinical reviewer and women's health specialist. "A written plan for meal timing and an antiemetic in the medicine cabinet before the first injection is the standard of care, not an optional extra."

Storage and preparation

Bremelanotide auto-injectors are stored in the refrigerator (36-46°F / 2-8°C) but can be kept at room temperature (up to 77°F / 25°C) for up to 30 days. Injecting a cold auto-injector directly from the refrigerator may increase injection-site stinging. Let it warm to room temperature for 15-30 minutes before injecting.

Injection site and skin

Rotate between the abdomen and thigh. Avoid areas with active acne, rashes, or scar tissue. Skin hyperpigmentation at the injection site, and more broadly on the face and gums, has been reported. The FDA label notes that focal hyperpigmentation may be permanent and occurs more frequently in women with darker skin tones. This is not a cosmetic afterthought; it should be part of informed consent before you start the drug.

Exercise and timing

No interaction between exercise timing and bremelanotide pharmacokinetics has been formally studied. Anecdotally, strenuous aerobic exercise in the 30-60 minutes around injection may worsen flushing because both exercise and melanocortin activation increase skin blood flow. Light activity (walking, gentle yoga) during the post-injection window appears to be tolerated by most women and may even reduce nausea by promoting gastric motility.

Mental state and context

Bremelanotide acts on desire, not arousal or lubrication. It requires a context in which sexual activity is anticipated. Women who report the most benefit in the RECONNECT trials had partners available and were in stable relationship contexts. This is not a medication you can evaluate in isolation from your overall sexual context. If stress, sleep deprivation, relationship conflict, or depression are the primary drivers of low desire, addressing those with evidence-based behavioral interventions alongside medication is appropriate clinical practice.

Tracking Your Response: What to Measure

The RECONNECT trials measured two primary endpoints: change in the number of satisfying sexual events per month and change in the desire domain of the FSFI. You can use the same metrics at home.

Keep a brief log for each dose:

• Time of injection and food eaten in the 2 hours prior.
• Nausea severity on a 0-10 scale and how long it lasted.
• Whether the sexual encounter occurred and whether desire was present.
• Any other side effects: flushing, headache, blood pressure symptoms, injection-site changes.

After 6-8 doses, bring this log to your provider. It gives your clinician objective data to decide whether to continue, adjust the antiemetic strategy, or consider alternative HSDD therapies.

Women in the RECONNECT trials who reported benefit showed statistically significant improvements in FSFI desire scores compared to placebo (bremelanotide: +0.4 on the FSFI desire subscale at week 24). That is a modest but statistically significant change; setting realistic expectations matters.